ARS Pharmaceuticals Inc. reported a larger-than-expected loss per share for Q1 2026, with EPS of -$0.61 missing the consensus estimate of -$0.49 by 24.49%.
Revenue came in at $22.7 million, slightly above the $22.67 million forecast. Following the announcement, the stock fell 8.56% in pre-market trading.
The stock currently trades at $7.63, down over 31% year-to-date, reflecting investor concerns about profitability.
The company's needle-free epinephrine treatment, Neffy, saw a threefold increase in prescriptions year-over-year, but high SG&A expenses weighed on the bottom line.
ARS Pharmaceuticals targets cash flow breakeven by mid-2027, with lower losses expected in the second half of 2026.
